Spravato® (Esketamine) Therapy for Treatment-Resistant Depression
The original ITS website describes Spravato® as an FDA-approved nasal spray for treatment-resistant depression. Treatment suitability, current indications, risks, and medication requirements must be reviewed with your prescribing clinician. Individual results vary.
A Breakthrough in Depression Care
Spravato® (esketamine) is a CIII controlled substance that is administered as a nasal spray. The source page describes its use alongside a traditional oral antidepressant for adults who have struggled to find relief from multiple treatments.
- A Unique Mechanism: Unlike most antidepressants that target serotonin or norepinephrine, Spravato® is an NMDA receptor antagonist. It works on a different pathway in the brain.
- Clinical research: The original page refers to clinical studies involving over 1,700 adult patients living with treatment-resistant depression. This does not predict an individual outcome.
- Targeted Support: The source describes use in conjunction with an oral antidepressant. Confirm your individual regimen with the clinical team.
What is treatment-resistant depression (TRD)?
Treatment-resistant depression is typically defined as a situation where an adult has tried at least two different antidepressant treatments at adequate doses and durations during a depressive episode but has not experienced significant improvement.
How is Spravato® different from other antidepressants?
Most oral antidepressants work by increasing levels of certain chemicals in the brain. Spravato® works by targeting the NMDA receptors. Ask your clinician about the expected effects and uncertainties in your individual case.
How is the treatment administered?
Spravato® is a nasal spray that you administer yourself under the direct supervision of a healthcare provider. The source states you will remain at the clinic for at least two hours of observation after each dose to ensure your safety and comfort. Confirm the treatment location and all requirements with the office.
What should I expect during my appointment?
During your visit, you will be in a comfortable, monitored environment. Because Spravato® can cause temporary sedation or changes in perception, you will need to arrange for a ride home from the clinic. The original website states that you should not drive or operate heavy machinery until the day after your treatment session. Follow your clinician’s current instructions, including any sleep-related requirements.
Is Spravato® safe?
Spravato® is FDA-approved and has been studied. Approval does not mean risk-free. Our clinical team will discuss risks and monitor you during and after each session to manage potential side effects.
How do I know if I qualify?
If you are an adult struggling with severe depression and have not seen results from at least two different oral antidepressants, discuss whether Spravato® may be appropriate with the care team. Eligibility requires a clinical assessment.
Take the Next Step Toward Healing
We are committed to helping you find a treatment plan that works. Contact the office or use the existing Hushmail appointment-request workflow. The original service page’s Google interest questionnaire is not reproduced here pending privacy and authorization review. This information is not a diagnosis or individualized medical advice.
